

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2009

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.03.2009 (Unaudited)	Quarter ended 31.03.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
1 (a) Net Sales	2,289	2,169	9,833
(b) Other Operating Income	226	112<	532
Total	2,515	2,281	10,365
2 Expenditure			
(a) Increase/Decrease in stock in trade and work in progress	(141)	70	104
(b) Consumption of raw materials	947	553	3,077
(c) Purchase of traded goods	304	411	1,583
(d) Employee cost	326	283	1,192
(e) Depreciation	42	51	182
(f) Other expenditure	463	447	2,022
(g) Total	1,941	1,815	8,160
3 Profit from operations before other income and interest(1-2)	574	466	2,205

Particulars	Quarter ended 31.03.2009 (Unaudited)	Quarter ended 31.03.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
4 Other Income	94	77	394
5 Profit before Interest(3+4)	668	543	2,599
6 Interest	-	-	3
7 Profit before tax(5-6)	668	543	2,596
8 Tax Expenses	263	198	934
9 Net Profit for the period(7-8)	405	345	1,662
10 Paid-up equity share capital (Face Value of Rs. 10 per Share)	230	230	230
11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year			7,881
12 Earnings Per Share (EPS) (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year	17.61	15.00	72.61
13 Public Shareholding			
- Number of Shares	9,120,955	9,120,955	9,120,955
- Percentage of Shareholding	39.60	39.60	39.60
14 Promoters and Promoter group shareholding			
a) Pledged/Encumbered			

Particulars	Quarter ended 31.03.2009 (Unaudited)	Quarter ended 31.03.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
- Number of Shares	2,365,920		
- Percentage of shares(as a % of total shareholding of promoter and promoter group)	17.01%		
- Percentage of shares(as a % of total share capital of the company)	10.27%		
b) Non-Encumbered			
- Number of Shares	11,543,747		
- Percentage of shares(as a % of total shareholding of promoter and promoter group)	82.99%		
- Percentage of shares(as a % of total share capital of the company)	50.13%		

Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on April 28, 2009.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2009.
- The Company discontinued the distribution of the anti-rabies vaccine, Rabipur from February 19, 2009, pursuant to the Award of the Arbitrator in the matter relating to the disputes between the Company, Novartis Vaccines and Diagnostics Inc. and Chiron Behring Vaccines Private Limited (CBVPL) regarding the non-renewal of the Distribution Agreement for Rabipur. The Company continues to hold 49% of the share capital of CBVPL.

- The break up of Net Sales is as follows:

Rs Million

	Quarter ended March 31, 2009	Quarter ended March 31, 2008	Growth %
Domestic Sales-Others	1,621	1,414	14.6%
Domestic Sales-Rabipur	92	361	-74.5%
Export Sales	576	394	46.2%
Total Sales	2,289	2,169	5.5%

- Despite the discontinuation of Rabipur distribution, total sales have grown by 5.5%. Excluding this impact, the comparable sales growth would have been 21.5%.
- For the quarter ended March 31, 2009, Other Income includes write back of excess provision for expenses amounting to Rs.49 million provided in the previous year and Deferred Tax Charge includes Rs.20 million pertaining to prior years.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The Board of Directors had, at its Meeting held on February 17, 2009, recommended a Final dividend of Rs.12.50 per Equity share of Rs.10 for the year ended December 31, 2008. The said dividend has been declared at the Annual General Meeting held on April 28, 2009 and will be paid on or after April 29, 2009.
- Information on investor complaints is furnished below:

Pending as on January 1, 2009	Received during the quarter	Disposed of during the quarter	Pending as on March 31, 2009
Nil	11	11	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR